5 completed, 3 unknown. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Unknown 3 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Glaucoma, Neovascular: new trials by email Literature Review of Glaucoma, Neovascular trials Research Report on Glaucoma, Neovascular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied Aflibercept (EYLEA, BAY86-5321), Topical IOP-lowering drugs - Glaucoma, Neovascular | Phase 3 | Completed | Bayer | 16 | 2018-10-03 | 2020-03-03 |
| Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG aganirsen - Ischaemic Central Retinal Vein Occlusion, Neovascular Glaucoma | Phase 2 / Phase 3 | Unknown | Gene Signal SAS | 333 | 2017-01-01 | 2016-10-31 |
| Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study Intravitreal ranibizumab - Glaucoma, Neovascular, Ranibizumab | Phase 3 | Unknown | LEANDRO CABRAL ZACHARIAS | 28 | 2016-10-01 | 2016-09-27 |
| Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients Aflibercept (Eylea, BAY 86-5321), Sham Injection - Glaucoma, Neovascular | Phase 3 | Completed | Bayer | 54 | 2015-04-02 | 2017-09-15 |
| An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. ranibizumab - Choroidal Neovascularization, Macular Edema | Phase 3 | Completed | Novartis Pharmaceuticals | 270 | 2013-09-26 | 2019-08-12 |
| Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma Subconjunctival Avastin, Ahmed Valve implant - Refractory Glaucoma | Phase 3 | Unknown | Vanak Eye Surgery Center | 40 | 2010-05-01 | 2010-05-24 |
| Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery? Triesence, balanced salt solution BSS - Glaucoma | Phase 2 / Phase 3 | Completed | Wills Eye | 77 | 2009-02-01 | 2018-07-10 |
| Oculusgen (Ologen) Glaucoma MMC Control in Estonia ologen (oculusgen) collagen matrix, MMC in Trabeculectomy - Open Angle Glaucoma, Angle Closure Glaucoma | Phase 3 | Completed | Pro Top & Mediking Company Limited | 20 | 2007-07-01 | 2017-06-27 |
Glaucoma (2) · Glaucoma, Angle-Closure (2) · Glaucoma, Open-Angle (2) · Choroidal Neovascularization (1) · Diabetic Retinopathy (1) · Exfoliation Syndrome (1) · Macular Edema (1)
Eye Diseases (8) · Ocular Hypertension (8) · Glaucoma (6) · Uveal Diseases (2) · Cardiovascular Diseases (1) · Choroid Diseases (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetic Angiopathies (1) · Endocrine System Diseases (1) · Iris Diseases (1) · Macular Degeneration (1) · Metaplasia (1) · Neovascularization, Pathologic (1) · Pathologic Processes (1)
Ranibizumab (2) · aflibercept (2) · GS 101 (1) · Hanks Balanced Salt Solution (1) · Trabeculectomy (1) · Triamcinolone (1) · salicylhydroxamic acid (1)
Bayer (2) · Gene Signal SAS (1) · LEANDRO CABRAL ZACHARIAS (1) · Novartis Pharmaceuticals (1) · Pro Top & Mediking Company Limited (1) · Vanak Eye Surgery Center (1) · Wills Eye (1)
Japan (2) · Estonia (1) · France (1) · Iran (1) · United States (1)
Kuldar Kaljurand, MD (1) · Marlene R Moster, MD (1)
PMID 37010901, PMID 24794283, PMID 28302155, PMID 33330958, PMID 33330959, PMID 36912740
2014 (1)